Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Increasing clinical investigations have explored the value of EGFR-TKIs plus antiangiogenic drugs as the first-line treatment fo...

Full description

Bibliographic Details
Main Authors: Fei Chen, Naifei Chen, Yu Yu, Jiuwei Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
epidermal growth factor receptor inhibitors
angiogenesis inhibitors
non-small cell lung cancer
EGFR mutation
anti-VEGF
targeted treatment
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00904/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00904/full

Similar Items